Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Other Non Operating Income (2022 - 2025)

Stoke Therapeutics has reported Other Non Operating Income over the past 4 years, most recently at -$110000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 154.73% year-over-year to -$110000.0; the TTM value through Dec 2025 reached -$51000.0, up 79.35%, while the annual FY2025 figure was -$51000.0, 79.35% up from the prior year.
  • Other Non Operating Income for Q4 2025 was -$110000.0 at Stoke Therapeutics, down from $3000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $201000.0 in Q4 2024 and troughed at -$428000.0 in Q1 2024.
  • A 4-year average of $2187.5 and a median of $41000.0 in 2023 define the central range for Other Non Operating Income.
  • On a YoY basis, Other Non Operating Income climbed as much as 390.24% in 2024 and fell as far as 1119.05% in 2024.
  • Year by year, Other Non Operating Income stood at $42000.0 in 2022, then decreased by 2.38% to $41000.0 in 2023, then soared by 390.24% to $201000.0 in 2024, then plummeted by 154.73% to -$110000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for STOK at -$110000.0 in Q4 2025, $3000.0 in Q3 2025, and $28000.0 in Q2 2025.